ARCA biopharma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.arcabio.com
Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT04655586
- Locations
- 🇺🇸
ARCA Investigational Site #119, Fairhope, Alabama, United States
🇺🇸ARCA Investigational Site #118, Phoenix, Arizona, United States
🇺🇸ARCA Investigational Site #120, Tucson, Arizona, United States
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
- Conditions
- Current or Recent History of Atrial Fibrillation
- Interventions
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 267
- Registration Number
- NCT01970501
- Locations
- 🇺🇸
ARCA Clinical Research Site #157, Anchorage, Alaska, United States
🇺🇸ARCA Clinical Research Site #383, Phoenix, Arizona, United States
🇺🇸ARCA Clinical Research Site #385, Phoenix, Arizona, United States
Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery
- Conditions
- Heart Disease
- First Posted Date
- 2008-12-16
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00808964
Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00499902
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Northwestern Medical Center, Chicago, Illinois, United States
🇺🇸Ruan Neurology & Clinical Research Center, Des Moines, Iowa, United States
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
- Conditions
- Colon Cancer
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2008-05-07
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00443573
- Locations
- 🇺🇸
LAC/USC Medical Center, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- Next